Over 12 months, Lyell Immunopharma, Inc. saw more buying than selling from its insiders — purchases of about $25 million against sales of $605,000.
ARCH Venture Partners IX Overage, L.P. (10% Owner) made the biggest buy, worth around $12.5 million.
86 investment managers listed LYEL in their latest 13F filings (Q2 2026); more funds bought than sold. Looking at the quarterly pattern: 2 quarters in a row of net selling by insiders. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Shook David | Executive Officer | Sell | 500 | $12.70 | $6K | SEC |
| Aug 25, 2026 | Seely Lynn | CEO | Sell | 9,589 | $15.54 | $149K | SEC |
| Aug 25, 2026 | Hill Stephen J. | COO | Sell | 989 | $15.54 | $15K | SEC |
| Aug 25, 2026 | Lee Gary K. | Executive Officer | Sell | 1,457 | $15.54 | $23K | SEC |
| Aug 11, 2026 | Bulis Veronica Sanchez | Officer | Sell | 621 | $14.34 | $9K | SEC |
| Aug 11, 2026 | Lee Gary K. | Executive Officer | Sell | 131 | $14.34 | $2K | SEC |
| Aug 11, 2026 | Hill Stephen J. | COO | Sell | 89 | $14.34 | $1K | SEC |
| Aug 11, 2026 | Seely Lynn | CEO | Sell | 390 | $14.34 | $6K | SEC |
| Jul 20, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | Sell | 10 | $13.70 | $137 | SEC |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | Sell | 10 | $13.73 | $137 | SEC |
| Jun 15, 2026 | Seely Lynn | CEO | Sell | 388 | $18.91 | $7K | SEC |
| Jun 15, 2026 | Lee Gary K. | Executive Officer | Sell | 130 | $18.92 | $2K | SEC |
| Jun 15, 2026 | Hill Stephen J. | COO | Sell | 89 | $18.92 | $2K | SEC |
| Jun 15, 2026 | Bulis Veronica Sanchez | Officer | Sell | 217 | $18.91 | $4K | SEC |
| Jun 11, 2026 | Shook David | Executive Officer | Sell | 1,977 | $12.64 | $25K | SEC |
In the last 12 months Lyell Immunopharma, Inc. insiders made open-market purchases worth about $25 million and sales worth about $605,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in LYEL was filed on 2026-09-10.
86 investment managers reported holding LYEL in SEC Form 13F filings for Q2 2026.
No congressional trades in LYEL were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).